Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605633 | 0.86 | HRH4 (0.42) | HRH4MAPK14MAPK11PIN1KIT | |
| SCHEMBL605637 | 0.86 | HRH4 (0.50) | HRH4MAPK14MAPK11PIN1KIT | |
| SCHEMBL606597 | 0.85 | CXCR1 (0.43) | HRH4MAPK14MAPK11PIN1MAPK13 | |
| SCHEMBL601781 | 0.85 | HRH4 (0.48) | HRH4MAPK14MAPK11KITCNR2 | |
| SCHEMBL2563887 | 0.84 | MAPK14 (0.42) | HRH4MAPK14MAPK11PIN1KIT | |
| SCHEMBL603572 | 0.84 | HRH4 (0.46) | HRH4MAPK14MAPK11KITMAPK13 | |
| SCHEMBL605187 | 0.83 | HRH4 (0.44) | HRH4KIT | |
| SCHEMBL603665 | 0.82 | KIT (0.40) | HRH4MAPK14KIT | |
| SCHEMBL605611 | 0.81 | HRH4 (0.44) | HRH4MAPK14MAPK11PIN1KIT | |
| SCHEMBL604458 | 0.80 | HRH4 (0.42) | HRH4MAPK14MAPK11KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | claimed |
| US-8039498-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-18 | — | — | US | claimed |
| EP-1737297-A4 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | claimed |
| US-20070265250-A1 | Imidazole compounds | BUZARD DANIEL J | 2007-11-15 | — | — | US | claimed |
| US-7253200-B2 | Using in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-07 | — | — | US | claimed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | claimed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | claimed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885MAPK14 2511/4885MAPK11 2824/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885MAPK14 2511/4885MAPK11 2824/4885 |
| US-20070265250-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885MAPK14 2511/4885MAPK11 2824/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885MAPK14 2511/4885MAPK11 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.